by R$1,011) and effectiveness (by 2.7%) were greater compared to VAN, resulting in an ICER of R$37,564 per successfully treated patients. But compared to TEI, LZD had lower costs (by R$2,246) and greater effectiveness (by 13.3%), with LZD being the 'dominating' treatment. Majority of treatment costs were related to hospital stay, primarily ICU (73% in private and 50% in public scenario). Several scenarios were tested by varying treatment duration (7or14 days), and varying discontinuation/ switch of therapy (at 5 or 10 days). Results for all scenarios were similar to the base case from public and private perspectives. CONCLUSIONS: From private perspective LZD is a cost-effective alternative to VAN and TEI for treatment of MRSA-confirmed NP, owing primarily to its higher clinical response rate. From public perspective, LZD can be considered cost effective since its ICER vs. VAN is within 2-3 times Brazil's GDP per capita. PIN50 SyStematIc LIterature revIew to IdeNtIfy coSt eStImateS of LIver dISeaSe IN thoSe wIth chroNIc hePatItIS c vIruS (hcv) IN the uNIted StateS Mauskopf J.
OBJECTIVES: The objective of the review was to determine the most widely used estimates of United States (US) costs of different stages of liver disease in patients with hepatitis C virus (HCV) in cost-effectiveness analyses (CEA). METHODS: A systematic literature search using predetermined search terms was performed to identify English-language articles that report cost or CEA from 1995 to 2014. Full texts were obtained and reviewed to determine study eligibility on the basis of predefined inclusion and exclusion criteria. All costs were inflated to 2014 values. RESULTS: A total of 53 articles were eligible for review. In primary cost studies, two methods were generally used to derive the disease state costs: microcosting using treatment algorithms and unit costs; or statistical analyses of observational databases. The most widely used primary cost estimates in CEAs completed before 2011 were those derived using treatment algorithms by Bennett and colleagues (1997) . A CEA published in 2012 by Gellad and colleagues presented updated resource use and costs for all the disease stages based on the Bennett study and added mild/moderate chronic HCV, compensated cirrhosis, and post-SVR health states. The most widely used primary cost estimates in CEAs completed after 2012 are those obtained from a large database study by McAdam-Marx and colleagues (2011). This study provides estimates for all liver stages but does not include subcategories for decompensated disease. The estimates from the different sources were quite different; for example, for cirrhosis and hepatocellular carcinoma Gellad estimated $745 and $45,728 per year while McAdam-Marx estimated $2,584 and $50,658 per year, respectively. CONCLUSIONS: There are many estimates of costs of HCV liver disease and these estimates can vary widely due to differences in study methodology. Understanding the differences in these estimates can aid in the selection of the most appropriate inputs for use in economic models.
PIN51 coSt-effectIveNeSS aNaLySIS of SofoSbuvIr baSed combINatIoN theraPIeS amoNg treatmeNt-NaÏve aNd Pre-treated PatIeNtS wIth hePatItIS c INfectIoN
Gaitonde P. 1 , Yerlikaya N. S. 2 , Chirikov V. V. 1 , Shaya F. T. 3 1 University of Maryland, Baltimore, MD, USA, 2 Hacettepe University, Ankara, Turkey, 3 University of Maryland School of Pharmacy, Baltimore, MD, USA OBJECTIVES: AASLD/IDSA have recently updated their treatment guidelines to include sofosbuvir-based therapy as recommended regimen for treatment-naïve and previously treated patients with hepatitis C (HCV) genotype 1 infection. The purpose of the study was to compare the cost-effectiveness of sofosbuvir-based combination therapies vs. peg-IFN and ribavirin (PEGIFN) among treatment-naïve patients and compare sofosbuvir-based combinations with and without interferon among patients previously treated with PEGIFN. METHODS: Cost per sustained viral response (SVR) was performed using a decision tree. It was assumed that patients were equally likely to receive either treatment. The model contained clinical data from Phase III clinical trials for PEGIFN (T1), sofosbuvir triple therapy (T2) (NEUTRINO study), and sofosbuvir plus simeprevir and/or ribavirin (T3) (COSMOS study); drug and medical costs were obtained from the National Average Drug Acquisition Costs Database (Medicaid) and literature. Time horizon was 48 weeks for both analyses. RESULTS: Average cost among the treatment-naïve was $79,749 for T1 arm (52% SVR), $101,317 for T2 (91% SVR), and $147,386 for T3 (94% SVR). Among the pre-treated, the average cost was $142,862 for T2 (72% SVR) and $187,664 for T3 (94% SVR). Among the treatment-naïve, an ICER of $553 and $719 per 1%SVR gain was obtained for T2 vs. T1 and T3 vs. T1, respectively. Among the pre-treated, an ICER of $2036 per 1%SVR was obtained for T3 vs. T2. In sensitivity analysis, no other factor but %SVR impacted incremental costs per responder. CONCLUSIONS: Although sofosbuvir-based combination without interferon was found to be the most expensive treatment it achieved the highest SVR rates among treatment-naive and pre-treated patients. The presented results can be used to make decisions by individual payers' based on their willingness to pay thresholds. Future studies should examine the cost-effectiveness of new therapies by relevant HCV patient subgroups. 
PIN47 treatmeNt coStS for uNcomPLIcated maLarIa at a SecoNdary heaLth care facILIty IN NIgerIa
Ezenduka C. C. Nnamdi Azikiwe University, Awka, Nigeria OBJECTIVES: Malaria treatment in health care facility represents a standard practice in malaria case management. The study estimated the costs of treatment for uncomplicated malaria from a healthcare facility, to generate current information for appropriate decision making in resource or funding allocations for malaria treatment and control in Nigeria. METHODS: Based on a comprehensive cost of illness approach, hospital associated costs of uncomplicated malaria episodes were estimated from a provider perspective, applying a standard costing procedure for outpatient services. Capital and recurrent expenditures were estimated using ingredient approach combined with step-down methodology to calculate the final costs. Costs attributable to malaria treatment were calculated based on the proportion of uncomplicated malaria cases treated within in the period. Non-hospital costs were not collected. Total and average financial and economic costs were estimated for uncomplicated malaria. All costs were calculated in local currency, converted to the US Dollars at the 2013 exchange rate. RESULTS: The hospital spent a total annual economic cost of N31.612 million (US$201,352.30) for the treatment of uncomplicated malaria, at US$34.66 per case. This represents about 20% of the hospital total expenditure within the year. Personnel accounted for over 81% of the expenditure as the dominant cost driver, followed by antimalarial drugs, 7.8%. Over 45% of outpatients visits were treated for malaria in the facility, leading to increased utilization of hospital resources. Changes in personnel costs, drug prices and malaria prevalence significantly impacted on the study results, indicating the need for improved efficiency in the hospital resource utilization. CONCLUSIONS: Malaria treatment at the medical center constitutes a considerable amount of hospital expenditure, arising mainly from the cost of personnel and high proportion of malaria treatment. For a more effective healthcare system, there is need for more efficient use of hospital resources to prevent wastages and reduce costs to the provider and consumer.
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